Imprimis Pharmaceutical

Imprimis Pharmaceuticals Inc (NASDAQ: IMMY), a nano-cap pharmaceutical company that owns, markets and dispenses a portfolio of compounded therapeutic in several areas, reported improved quarterly results on a year-over-year basis. The company reported a loss of $0.44 per share in the fourth quarter...

Imprimis Pharmaceuticals Inc (NASDAQ: IMMY) owns, markets and dispenses a portfolio of compounded therapeutic in various areas, including ophthalmology, urology, otolaryngology and infectious diseases. Benzinga had the privilege of chatting with the company's CEO, Mark Baum, about its most recent...